DE60234831D1 - Gonadotropin releasing hormone antagonist in gel-formenden konzentrationen - Google Patents

Gonadotropin releasing hormone antagonist in gel-formenden konzentrationen

Info

Publication number
DE60234831D1
DE60234831D1 DE60234831T DE60234831T DE60234831D1 DE 60234831 D1 DE60234831 D1 DE 60234831D1 DE 60234831 T DE60234831 T DE 60234831T DE 60234831 T DE60234831 T DE 60234831T DE 60234831 D1 DE60234831 D1 DE 60234831D1
Authority
DE
Germany
Prior art keywords
gel
releasing hormone
hormone antagonist
forming concentrations
gonadotropine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234831T
Other languages
German (de)
English (en)
Inventor
Martin Lueck
Pierre Broqua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of DE60234831D1 publication Critical patent/DE60234831D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60234831T 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonist in gel-formenden konzentrationen Expired - Lifetime DE60234831D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition
PCT/GB2002/003116 WO2003006049A1 (en) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonists in gel-forming concentrations

Publications (1)

Publication Number Publication Date
DE60234831D1 true DE60234831D1 (de) 2010-02-04

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234831T Expired - Lifetime DE60234831D1 (de) 2001-07-12 2002-07-08 Gonadotropin releasing hormone antagonist in gel-formenden konzentrationen

Country Status (13)

Country Link
US (4) US20040038903A1 (https=)
EP (1) EP1404357B1 (https=)
JP (1) JP4845166B2 (https=)
AR (1) AR036337A1 (https=)
AT (1) ATE452648T1 (https=)
DE (1) DE60234831D1 (https=)
DK (1) DK1404357T3 (https=)
ES (1) ES2338217T3 (https=)
GB (1) GB0117057D0 (https=)
MY (1) MY139203A (https=)
PT (1) PT1404357E (https=)
UY (1) UY27378A1 (https=)
WO (1) WO2003006049A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
BRPI0314546B8 (pt) 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
AU2007339280B2 (en) * 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
PL4512390T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Wytwarzanie degareliksu
ITMI20121638A1 (it) 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
EP2925339B1 (en) 2012-11-28 2020-04-29 United-AH II, LLC Method for synchronizing time of insemination in gilts
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2589322T3 (es) * 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) * 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
KR20140063602A (ko) * 2011-07-15 2014-05-27 훼링 비.브이. 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법

Also Published As

Publication number Publication date
PT1404357E (pt) 2010-03-16
MY139203A (en) 2009-08-28
EP1404357B1 (en) 2009-12-23
DK1404357T3 (da) 2010-05-03
ATE452648T1 (de) 2010-01-15
ES2338217T3 (es) 2010-05-05
JP2005511491A (ja) 2005-04-28
US20040038903A1 (en) 2004-02-26
EP1404357A1 (en) 2004-04-07
US20050245455A1 (en) 2005-11-03
US20090018085A1 (en) 2009-01-15
UY27378A1 (es) 2003-02-28
GB0117057D0 (en) 2001-09-05
AR036337A1 (es) 2004-09-01
JP4845166B2 (ja) 2011-12-28
WO2003006049A1 (en) 2003-01-23
US20110053846A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DE60234831D1 (de) Gonadotropin releasing hormone antagonist in gel-formenden konzentrationen
NL301115I2 (nl) Drospirenon in combinatie met estetrol
EE200200400A (et) Kortikotropiini vabastava faktori antagonistid
NO20003196L (no) Umiddelbart opplösende doseringsformulering
EE05350B1 (et) Antiproliferatiivsete vahenditena kasutatavad bensoimidasooli derivaadid
DE60303407D1 (de) Mehrachsige Schleifenantenne in Chip-Form
DE69923766D1 (de) Protonendonatoren in saugkörpern
FI20000819L (fi) Menetelmä vastaanottimessa ja vastaanotin
FI20000480A0 (fi) Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
DE10085381T1 (de) Lötpasten-Kontrollsystem
ITMI20031127A0 (it) Anticorpi anti-hgf e loro uso
EE200300247A (et) Isotiasool-4-karboksamiidi soolad ja nende kasutamine hüperproliferatsioonivastaste vahenditena
DE60226425D1 (de) Lösliches rage-protein
PL358622A1 (pl) Związki difenyloeterowe przydatne w terapii
DE60122160D1 (de) Antennenstruktur und zugehöriges verfahren
BR0312184B1 (pt) terminal para zÍper e zÍper tendo o mesmo
DE60033971D1 (de) Supraleitendes mikrostreifenfilter
DE60144265D1 (de) Halbleiterbauelement und dessen herstelllung
ATA20462000A (de) Rettungstunnel im tunnel
IS8360A (is) Mótlyf styrkthjöppunarhormóns melaníns
AR028589A1 (es) PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE BIFENILO Y PROCEDIMIENTO PARA REDUCIR EL NIVEL DE DíMERO AQUIRAL EN LOS COMPUESTOS DE BIFENILO PREPARADOS
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
DE60137845D1 (de) Rauscharmes spektroskopisches ellipsometer
ATA5832000A (de) Strumpfhose
AU2002319415A1 (en) Gonadotropin releasing hormone antagonists in gel-forming concentrations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition